Lovenox Patent Re-Issuance Denied: Aventis To Submit Response Shortly
Executive Summary
Aventis plans to submit additional information on Lovenox to the Patent & Trademark Office after the agency denied re-issuance of a patent central to the company's defense against enoxaparin generics